Foghorn Therapeutics Files 8-K

Ticker: FHTX · Form: 8-K · Filed: Dec 16, 2024 · CIK: 1822462

Foghorn Therapeutics Inc. 8-K Filing Summary
FieldDetail
CompanyFoghorn Therapeutics Inc. (FHTX)
Form Type8-K
Filed DateDec 16, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, regulatory-filing, financials

TL;DR

Foghorn Therapeutics filed an 8-K on 12/16/24 covering Reg FD, other events, and financials.

AI Summary

Foghorn Therapeutics Inc. filed an 8-K on December 16, 2024, reporting on various events. The filing includes information related to Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The company is incorporated in Delaware and headquartered in Cambridge, MA.

Why It Matters

This 8-K filing provides updates on regulatory disclosures, other significant events, and financial statements for Foghorn Therapeutics Inc., which could impact investor understanding of the company's current status.

Risk Assessment

Risk Level: low — The filing is a standard 8-K reporting routine events and financial information, not indicating immediate or significant new risks.

Key Players & Entities

  • Foghorn Therapeutics Inc. (company) — Registrant
  • December 16, 2024 (date) — Date of earliest event reported
  • Cambridge, MA (location) — Principal executive office address

FAQ

What is the primary purpose of this 8-K filing for Foghorn Therapeutics Inc.?

This 8-K filing serves to report on Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits for Foghorn Therapeutics Inc., as of December 16, 2024.

When was the earliest event reported in this filing?

The earliest event reported in this filing occurred on December 16, 2024.

Where is Foghorn Therapeutics Inc. headquartered?

Foghorn Therapeutics Inc. is headquartered at 500 Technology Square, Suite 700, Cambridge, MA 02139.

What is the state of incorporation for Foghorn Therapeutics Inc.?

Foghorn Therapeutics Inc. is incorporated in Delaware.

What is the SEC file number for Foghorn Therapeutics Inc.?

The SEC file number for Foghorn Therapeutics Inc. is 001-39634.

Filing Stats: 543 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-12-16 07:04:36

Key Financial Figures

  • $0.0001 — ge on which registered Common Stock, $0.0001 par value per share FHTX The Nasdaq Glo

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. Foghorn Therapeutics Inc. (the "Company") is furnishing as Exhibit 99.1 to this Current Report on Form 8-K a presentation, dated December 2024, which the Company plans to use in meetings with or presentations to investors. The information in this Item 7.01 (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Other Information

Item 8.01 Other Information. On December 16, 2024, the Company issued a press release announcing that it will discontinue the independent development of FHD-286 in combination with decitabine in patients with relapsed or refractory acute myeloid leukemia. A copy of the Company's press release is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits 99.1 Investor Presentation dated December 2024 99.2 Press release issued on December 16 , 2024

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FOGHORN THERAPEUTICS INC. By: /s/ Kristian Humer Kristian Humer Chief Financial Officer Date: December 16, 2024

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.